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Abstract
Parkinson’s Disease is one of the most common neurological disorders which disrupts the everyday lives of millions of people.  This 
disease is categorized by the loss of dopamine in the brain, specifically the Substantia Nigra.  People diagnosed with PD suffer 
from motor and cognitive impairments .  While there is no one treatment which can completely cure the disease, there are many 
treatments available which can help alleviate symptoms .  However, most of the treatments cause many negative side effects . 
Recently, a new physical therapy treatment, LSVT BIG has begun to show its effects .  This revue describes the many factors and 
treatments of Parkinson’s disease and explains the newly discovered treatment of LSVT BIG.
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Introduction
Parkinson’s disease (PD) is a progressive neurological 
disorder which disturbs one’s motor cortex, thereby 
affecting one’s mobility. This disorder affects over one 
million people in the United States alone and more than 
ten million across the entire world (National Parkinson’s 
Foundation, n.d.). Unfortunately, this disease slowly wors-
ens from the time one is diagnosed. Even more, PD has 
a large range of indications and effects. While many with 
Parkinson’s disease have similar symptoms, no two indi-
viduals experience the illness in exactly the same way. If 
you see someone shuffling down the street taking small 
steps or shaking their hands quickly and repeatedly in 
their lap, you can suspect that this person is suffering 
from Parkinson’s Disease. What causes this neurological 
disease, and what can we do to slow the progression and 
treat the symptoms? 
Methods
The information stated in the following paper was ac-
quired through the Touro College Library, which grants 
its students access to many useful databases such as 
ProQuest, Ebsco, PubMed and others. 
Pathophysiology
Patients with Parkinson’s Disease are lacking in dopa-
mine, which is normally produced in the substantia nigra 
part of the brain. The thalamus must have access to the 
motor cortex in the brain, specifically to the basal ganglia, 
in order to produce movement. Within the basal ganglia 
there are two pathways which have opposite effects on 
movement. The direct loop promotes movement, while 
the indirect loop inhibits movement. In a healthy person, 
the dopaminergic pathway maintains the balance between 
the other two pathways, enabling the thalamus to have 
control over the motor cortex and over the person’s 
movements. This dopaminergic pathway works by excit-
ing the direct pathway, while inhibiting the indirect path-
way to promote movement. This happens in two ways. 
First, the substantia nigra sends dopamine to the stria-
tum which excites the striatum and causes it to inhibit 
the globus pallidus. Thus, the globus pallidus is unable to 
obstruct the thalamus. Second, the substantia nigra sends 
dopamine directly to the globus pallidus, inhibiting it, so it 
cannot prevent the thalamus from controlling the motor 
cortex. In those with PD, much of the dopamine in the 
substantia nigra is exhausted. Consequently, the globus 
pallidus is excited and inhibits the thalamus. Thus, the 
thalamus has little control over the motor cortex (Singh, 
2018). See Figure 1.
Figure 1: GPi = Globus Pallidus internus, GPe = Globus 
Pallidus externus, SNpr = Substantia Nigra, STN = 
Subthalamic Nucleous, MC = Motor Cortex, PMC = Pre 
Motor Cortex, SMA = Supplementary Motor Cortex 
The arrows thickness represents the amount of increase 
and decrease of neuronal actions. In the healthy person, 
the arrows of the direct and indirect pathways which are 
related to dopamine (explained above) are significantly 
thicker than the arrows in the PD patient. Furthermore, 
the Globus Pallidus internus has the power to inhibit the 
thalamus in the PD patient as demonstrated by the thick-
ness of the arrows (Singh, 2018).
The lack of dopamine causes akinesia, bradykinesia and 
other motor deficits which are so commonly found in 
patients with PD. As the levels of dopamine decrease, the 
levels of Acetylcholine (Ach) increase. The increased Ach 
is what causes the symptoms of tremors and rigidity in 
PD patients. In other words, the loss of the dopaminergic 
system leads to disinhibition of the cholinergic system 




Another major marker for Parkinson’s Disease is the 
existence of the Lewy Body. The Lewy Body is a “neuronal 
inclusion” which mainly contains a cluster of a-synuclein 
proteins (Bridi & Hirth, 2018).
Causes of Parkinson Disease
PD is believed to be an idiopathic disease being that 
scientists are unable to find one definitive cause of this 
Parkinson’s disorder. However, there are factors that 
increase one’s likelihood of developing Parkinson’s dis-
ease. First, there are those who have a genetic predispo-
sition. The most established or proven genetic cause of 
Parkinson’s is mutations in what is known as the Parkin 
gene (Park2) (Shadrina, et al., 2007) or the PINK1 gene 
(PARK6) as they both inhibit normal mitochondrial func-
tion (Seirafi, et.al. 2015). Additionally, people who experi-
ence a head injury are at a greater risk for developing PD. 
High milk and dairy intake and exposure to pesticides can 
also increase one’s risk for developing PD. Interestingly, 
research has found that there are certain steps one can 
take in order to reduce his/her risk of developing the dis-
ease, such as cigarette smoking and consumption of cof-
fee or other caffeinated drinks (Ascherio & Schwarzchild, 
2016).
Symptoms of Parkinson’s Disease
PD is a progressive disorder, meaning there is no cure 
and the disease slowly worsens over time. Most people 
consider PD a disease which only affects movement, how-
ever this is not the case. Rather, Parkinson’s causes a large 
range of symptoms and affects different systems in the 
body. Individuals suffering from PD perceive the world 
as much smaller than healthy individuals. Therefore, many 
of the symptoms are correlated to this viewpoint. For 
example, when a PD patient shuffles, one thinks that s/he 
is walking normally. (Fox, et.al. 2011). 
Motor Symptoms
There are two groups of symptoms caused by PD. First, 
and more well recognized, are motor symptoms. Up 
to 80% of dopamine in the Substantia Nigra is deplet-
ed before these motor symptoms become noticeable. 
However, in order to be diagnosed with PD, people must 
demonstrate some symptoms. First, they must exhibit 
slow movement and low amplitude of everyday move-
ments (shuffling of gait), otherwise known as bradykinesia. 
Then, they must also display one additional cardinal sign 
of Parkinson’s, which include rigidity, akinesia or unable to 
initiate movement, lack of balance or tremors. As men-
tioned above, about 80% of PD patients suffer from limb 
tremors, usually concerning the hand, which is caused by 
increased levels of Ach. Furthermore, several years after 
initial symptoms, 25% -60% of patients with PD exhibit 
frozen movements, while 40% – 80% of PD patients have 
swallowing issues and 25% drool. Additionally, more than 
50% suffer from speech impairments including quiet and 
hurried speech (Sveinbjornsdottir, 2016).  Additionally, 
those with PD display a masked expression, also known 
as bradykinesia of the face. This happens because when 
a person is suffering from Parkinson’s Disease, all move-
ments slow down including facial movements. The delay 
of the facial muscles is what causes PD patients to lose 
their ability to express themselves via facial expressions 
(Bologna, et al., 2013). 
Non-Motor Symptoms
Contrary to popular belief, Parkinson’s is not just a 
movement disease, rather it affects non-motor abilities 
as well. Even before the motor symptoms start and the 
person is diagnosed, patients may experience a variety 
of non-motor symptoms. These symptoms can be divid-
ed into three sections: autonomic function disturbanc-
es, sleep disturbances and neuropsychiatric symptoms 
(Sveinbjornsdottir, 2016). 
Autonomic Function Disturbances
Those with PD often experience rapid drops in blood 
pressure causing dizziness, visual troubles and weak-
ened cognition which can ultimately cause loss of 
consciousness. Furthermore, the movement of the 
gastrointestinal tract slows down. This can cause over-
stuffed feelings, gastric retention and constipation. 
Constipation occurs in over 75% of PD patients. Also, 
those with Parkinson’s suffer from an inability to con-
trol their urinary frequency and urgency. About 60% 
of PD patients display frequent nocturia, needing to 
wake up several times throughout the night to use the 
bathroom (Sveinbjornsdottir, 2016).
Sleep Disturbances
Roughly two thirds of PD patients suffer from an as-
sortment of sleep disorders. This can be due to physi-
cal or cognitive limitations of the disease itself, or due 
to the different medications and treatments which are 
being used to treat the patient’s symptoms. The most 
common ailment is fractionated sleep. Studies show that 
PD patients sleep lighter and have regular interruptions 
throughout the night. This fractionated sleep can also be a 
result of other PD sleep disorders such as frequent noc-
turia, difficulties with moving in bed and nocturnal trem-
ors. Depression caused by Parkinson’s can also disturb a 
patient’s sleep throughout the night.  Additionally, about 
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50% of people diagnosed with Parkinson’s undergo ex-
treme daytime sleepiness. Some say that this is somewhat 
caused by the dopaminergic drugs. Even more, 27-32% 
of PD patients kick and smack while dreaming and oth-
ers uncontrollably jerk while sleeping (Sveinbjornsdottir, 
2016). 
Neuropsychiatric Symptoms
Many with PD suffer from various Neuropsychiatric 
Symptoms. The earliest indications consist of executive 
functioning issues, visuospatial disfunction, weakened 
speech fluency and memory loss. Additionally, in more 
than a third of PD patients experience hallucinations 
and illusions. Also, as the disease progresses some de-
velop paranoia, particularly feeling suspicious towards 
their spouse. Moreover, dementia is also common in 
those with Parkinson’s. Other common Neuropsychiatric 
symptoms include depression and anxiety. One third of 
PD patients have clinically diagnosed depression and 17% 
were confirmed to have a major depressive disorder 
(Sveinbjornsdottir, 2016). All symptoms, whether they are 
movement related or not, adversely affects the lives of 
PD patients. 
Unified Parkinson’s Disease Rating Scale
For any disease, when testing a new treatment, or tweak-
ing a current treatment, there must be a way to measure 
the success. Specifically for Parkinson’s disease, there are 
different ways of measuring the severity of PD symp-
toms, thereby displaying the treatments progress. Most 
frequently used is the Unified Parkinson’s Disease Rating 
Scale (UPDRS). This rating tool is used to determine the 
severity of the PD patient’s symptoms. It is divided into 
four sections which evaluate the symptoms’ severity on 
a 0-4 scale. First, UPDRS I measures non-motor daily be-
haviors such as sleep, mood and brain activity. Second, 
UPDRS II assesses the patient’s motor abilities for daily 
living, such as speech, chewing, handwriting, walking and 
drooling. Third, UPDRS III is the section which includes 
motor evaluation such as rigidity, gait and tremors. Last, 
UPDRS IV calculates treatment complications such as 
pain (Kleiner-Fisman, et.al. 2010). 
Brief Overview of PD treatments
Although there is not a single cure for PD, there are 
different treatments which target specific symptoms of 
the disease. This includes both motor symptoms and 
non-motor symptoms. Furthermore, there are three 
types of treatments used to improve PD patient’s way of 
life. There are medicinal treatments, surgical intervention 
and physical therapies. 
Drug Therapy
Many of the medicinal treatments for Parkinson’s Disease 
patients target the dopaminergic pathway, working to 
increase the dopamine in the patient’s brain. While 
some medicines work better than others, no drug cures 
symptoms completely. The most commonly used drug 
is levodopa which increases the dopamine in the brain. 
Primarily, levodopa targets the movement disorders of 
PD. Although levodopa is still considered the most ef-
fective treatment, about 40% of patients develop motor 
complications after 4-6 years of levodopa treatments. 
There are other drugs taken to combat the side effects 
of levodopa (Dong, et.al. 2016). Another commonly used 
drug is amantadine. Many clinical trials have proved that 
amantadine can lessen the dyskinesia side-effect of the 
levodopa drug. It was also found to reduce the severity 
of freezing gait. Thus, improving PD patients’ abilities to 
perform daily activities. Additionally, there are less fre-
quently used drugs such as anticholinergic drugs. These 
drugs help by restoring the balance between dopamine 
and acetylcholine. Anticholinergic drugs are mostly used 
at the onset of the disease, when the primary symptom 
is tremors. The use of this type of medication is very lim-
ited, as there are many side-effects which some believe 
outweigh the benefits (Dong, et.al. 2016). Side-effects 
include decreased cognitive function, especially in older 
PD patients, constipation, blurred vision and tachycardia 
(Lertxundi, et al., 2015).
Surgical Treatments
There are many surgical interventions which were prov-
en to be beneficial for PD patients. One such method is 
called Deep Brain Stimulation (DBS). This surgery places 
electrodes at certain places in the brain which control 
movements. They are either placed in the subthalamic 
nucleus (STN), the globus pallidus interna (GPi), or the 
ventralis intermedius (VIM) nucleus of the thalamus. DBS 
improves patients’ movement abilities and may lessen 
tremor severity. Yet, unlike other pharmaceutical drugs, 
DBS has demonstrated little to no side-effects (Chou, 
Grube, & Patil, 2012, p. 15). Another surgical treatment 
is cell transplantation. This treatment has proven to be 
effective on motor symptoms of PD. This works as the 
transplanted stem cells can “infiltrate and integrate with 
diseased tissue, differentiate into dopaminergic neurons 
to replace damaged cells and reconstruct neuronal cir-
cuits to restore nerve function (Li, 2012).” 
Physical Therapy
A major issue with medication for PD patients is that the 
effectiveness of the medicinal drugs decreases over time. 
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As a result, the creation of different exercises and physical 
therapies have also proven to be an effective way of com-
bating Parkinson’s disease. First, basic exercises lessen the 
motor and even non-motor symptoms of those with PD. 
Exercise increases mitochondrial respiration and arouses 
neuroplasticity. Furthermore, recent clinical trials recom-
mend aerobic exercises. They claim that these exercises 
improve gait, physical performance and balance. They also 
state that they impact fatigue, depression and improve 
cognitive ability. Additionally, a Chinese exercise called 
Tai Chi, through breathing exercises combined with slow 
movements, has improved the balance of PD patients 
(Dong, et.al. 2016). Finally, LSVT BIG, a relatively new ap-
proach to physical therapy in PD, has begun to show its 
effectiveness.  
What is LSVT BIG?
LSVT Big was created based on the success of a treat-
ment called LSVT Loud. First introduced in 1995, LSVT 
Loud was proven to be an effective way of improving the 
strength and loudness of the voice of PD patients.  LSVT 
Loud is a treatment which focuses on how one feels and 
sounds when talking loudly. Unlike many speech treat-
ments which target many different speech systems, LSVT 
Loud primarily focuses on increasing movement in the 
respiratory and laryngeal systems. Currently, after con-
ducting many studies and experiments, LSVT Loud was 
proven to be a successful treatment (Fox, et.al. 2011). 
After the success of LSVT-Loud, in 2005 LSVT-BIG was 
first introduced (McDonnell, et al., 2017). 
LSVT-BIG was created to combat the hypokinesia or 
reduced amplitude movements which interfere with the 
everyday lives of people with PD.  The goal of the treat-
ment is to revise the way the patient perceives movement 
performance.  LSVT BIG therapy includes four consecu-
tive, one on one, 60-minute sessions per week in addition 
to one (on treatment day) or two (non-treatment days) 
15 to 20-minute home sessions per day. When performing 
any action, patients are told to conduct large amplitude 
movements. The beginning of each out-session includes 
seven whole-body exercises such as reaching in more 
than one direction, weight shifting and stepping. Next, the 
patient works on five every-day movements, such as shift-
ing positions, rolling over in bed and any others that the 
patient requests to improve. Third, the patient practices 
walking with larger amplitude, while standing straight. At 
the end of the session, the patient works on more compli-
cated tasks which are directly related to his/her goals and 
abilities. Later in the treatment, this final segment would 
increase in difficulty by either adding an additional task or 
by enhancing the existing mission (Isaacson, et.al. 2018). 
Experiments Conducted 
To prove the effectiveness of LSVT-BIG, there were nu-
merous studies and experiments done on all different 
types of people at all stages of Parkinson’s disease. One 
such experiment performed, compared the results of 41 
patients involved in general exercise to 43 patients par-
ticipating in the LSVT-BIG program. After sixteen weeks, 
they found the motor function of the LSVT-BIG patients 
to have improved significantly more than the other 41 
patients. Additionally, it was found that those participating 
in the program increased their speed of moving. Another 
study found that LSVT-BIG helped decrease response 
time when prompted (McDonnell, et al., 2017). 
Another study was done to see if LSVT-BIG also im-
pacted the duration of a patient’s ‘off time,’ meaning the 
time of day where one feels at his/her low. Eight patients 
participated in the study. Before starting treatment, each 
patient was required to report their ‘on’ and ‘off ’ dura-
tions for three days. Then they were evaluated under the 
UPDRS III scale on motor ability. Then they began treat-
ment. The changes were measured every four weeks by 
ministering different tests. The results proved that LSVT-
BIG therapy does lessen the duration of ‘off ’ time as it 
did significantly improves the UPDRS III scores (Ueno, et 
al., 2017). 
In addition, a non-controlled study was performed 
which examined the effects that LSVT BIG had on eigh-
teen PD patients. It was found that after just four weeks of 
therapy, the participants experienced a 12-14% increase 
in walking and walking rate (Fox, et.al. 2011). 
A different blind study was done which took sixty peo-
ple suffering from Parkinson’s disease and randomly as-
signed them to one of three therapies, LSVT BIG, Nordic 
Walking in a group setting, or regular exercise with no 
therapist. After four months of treatment, the average 
improvement of the scores on the UPDRS III on patients 
receiving LSVT BIG therapy was 5.05, while the scores of 
those undergoing Nordic Walking or domestic training 
worsened. This amount of scaled motor increase clinically 
proves that LSVT BIG does improve the symptoms of PD 
patients (Fox, et.al. 2011). 
Another case study included twelve idiopathic PD pa-
tients who underwent LSVT BIG therapy treatment. There 
were also two control groups: one with eight PD patients 
who did not undergo any physical therapy and the other 
included fourteen healthy individuals who experienced 
the same experiment as the case study. The PD LSVT BIG 
patients were given sixteen sessions, four sessions per 
week for four weeks. Each session was an individualized 
meeting with a licensed LSVT BIG therapist and lasted 
one hour each morning. Each appointment began with 
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using the patient’s entire body including “BIG” amplitude 
exercises and “repetitive multidirectional movements.” 
The second half of the meeting included daily activities 
according to what the patient wished to focus on such as 
buttoning shirts and putting on a coat. The results showed 
the gait speed and the step length of patients undergoing 
LSVT BIG increased. Furthermore, the LSVT BIG patients 
displayed better functional mobility as they were able to 
transition from sitting to standing faster and more often. 
The LSVT BIG patients’ improvements were significantly 
greater than the PD control group (Flood, et al., 2020).
Each of the experiments described above prove the 
effectiveness of LSVT BIG therapy. There were countless 
of other case studies conducted whose results were sim-
ilar to the outcomes stated previously. Thus, it is safe to 
conclude that LSVT BIG is an effective way of treating 
Parkinson’s disease.
Conclusion 
Parkinson’s Disease is a neurological disorder which af-
fects tens of millions of people across the world. Primarily, 
the disease is associated with progressive loss of dopa-
mine in the brain. People with PD are affected in many 
different areas of life including motor skills and cognitive 
abilities. Unfortunately, researchers have not found one 
perfect solution to completely cure Parkinson’s Disease. 
Rather, there are only palliative solutions, treatments 
which either ease the symptoms or slow the progression 
of the disease however, doctors don’t often give patients 
medication for two reasons. Often, many of the com-
monly used medicinal treatments can cause difficult side 
effects. Secondly, as time progresses, the impact the medi-
cine has on the body weakens as the patient becomes ac-
customed to the drug. Therefore, doctors and therapists 
are beginning to use more non-invasive treatments such 
as exercise and Physical Therapy. Recently, there has been 
a new treatment, LSVT BIG, which targets the ampli-
tude of the PD patients. This treatment has continuously 
proved itself effective and worthwhile. Every Parkinson’s 
patient should have the opportunity to undergo LSVT 
BIG treatment.
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